STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis.
STARD10 is associated with poor prognosis in HER2+ breast cancer and enhances tumor growth and metastasis, suggesting it may be a target for future therapeutic strategies.
Where it sits
this study against the rest of the 5-amino-1mq corpusSummary and findings
This study examined the role of STARD10 in HER2+ breast cancer, focusing on its expression and impact on tumor progression. STARD10 was found to be upregulated in cancer tissues, and its overexpression led to increased cell proliferation and metastasis. The study utilized various assays and in vivo models to assess these effects.
Abstract
<h4>Background</h4>Although targeted therapies have improved clinical outcomes, HER2+ breast cancer remains a significant clinical challenge due to its aggressive behavior and unfavorable prognosis. Emerging evidence indicates that dysregulated lipid metabolism plays a critical role in tumorigenesis and metastasis, suggesting that targeting lipid metabolism may represent a promising therapeutic strategy. STARD10, a lipid transport protein, plays a pivotal role in regulating lipid metabolism. However, its function in mediating lipid metabolism and tumor progression in HER2+ breast cancer remains unclear.<h4>Methods</h4>The expression level and prognostic relevance of STARD10 in HER2+ breast cancer were analyzed using public databases and clinical cohorts. CCK-8, EdU, colony formation, transwell, LD540, and Nile Red staining assays were performed in SKBR3 and HCC1954 cells. Subcutaneous implantation and tail vein injection were performed to evaluate the effects of STARD10 overexpression on tumor growth and lung metastasis in vivo. The mechanism was validated by RNA-seq and Western blotting.<h4>Results</h4>STARD10 expression was upregulated in HER2+ breast cancer tissues and was significantly correlated with poor prognosis. Functionally, STARD10 overexpression enhanced HER2+ breast cancer cell proliferation, migration, invasion, and lipid droplets accumulation. Moreover, STARD10 overexpression markedly accelerated tumor growth and lung metastasis in vivo. Mechanistically, STARD10 was found to drive malignant phenotypes via activation of the cAMP/PKA/CREB1 signaling axis.<h4>Conclusion</h4>STARD10 promotes malignant progression of HER2+ breast cancer and lipid droplets accumulation by activating the cAMP/PKA/CREB1 pathway. These findings suggest that STARD10 and the cAMP/PKA/CREB1 signaling axis as potential therapeutic targets for the treatment and prevention of HER2+ breast cancer.
Background
This paper addresses the role of STARD10 in HER2+ breast cancer, a subtype known for its aggressive nature and poor prognosis. Previous research has suggested that lipid metabolism is crucial in cancer progression, yet the specific mechanisms involving STARD10 remain poorly understood. Understanding STARD10's function could provide insights into new therapeutic strategies targeting lipid metabolism in this cancer type.
Methods
The study utilized public databases and clinical cohorts to analyze STARD10 expression and its prognostic relevance. Various assays, including CCK-8, EdU, colony formation, transwell, LD540, and Nile Red staining, were conducted in SKBR3 and HCC1954 cell lines. In vivo effects were evaluated through subcutaneous implantation and tail vein injection to assess tumor growth and metastasis.
Results
STARD10 expression was significantly correlated with poor prognosis in HER2+ breast cancer. Overexpression of STARD10 led to enhanced proliferation, migration, invasion, and lipid droplet accumulation in cancer cells. Additionally, STARD10 overexpression markedly accelerated tumor growth and lung metastasis in vivo.
Interpretation
The findings suggest that STARD10 plays a significant role in promoting malignant characteristics of HER2+ breast cancer, aligning with prior literature indicating the importance of lipid metabolism in cancer progression. However, the clinical significance of these findings may be limited by the reliance on in vitro and animal models, which may not fully translate to human patients. Further studies are needed to explore the therapeutic implications of targeting STARD10 and the associated signaling pathways.
Key findings
- STARD10 expression was upregulated in HER2+ breast cancer tissues.
- STARD10 overexpression enhanced cell proliferation, migration, invasion, and lipid droplets accumulation.
- STARD10 significantly accelerated tumor growth and lung metastasis in vivo.
Limitations
- Relies on in vitro and in vivo models, not human data.
- Potential confounding factors in clinical cohort analysis.
- Not all relevant numeric findings reported in abstract.